Skip to main content
Eurobio Scientific logo

Eurobio Scientific — Investor Relations & Filings

Ticker · ALERS ISIN · FR0013240934 LEI · 969500IQEUEH806GE257 PA Manufacturing
Open in API
Filings indexed 198 across all filing types
Latest filing 2024-07-23 Report Publication Anno…
Country FR France
Listing PA ALERS

About Eurobio Scientific

https://www.eurobio-scientific.com

Eurobio Scientific is an integrated company specializing in in vitro diagnostics (IVD). Its activities cover the entire value chain, from research and development to the manufacturing and commercialization of specialty diagnostic products. The company's core focus areas are transplantation, oncology, and infectious diseases. In transplantation, it provides reagents, software for transplant matching and chimerism monitoring, and culture media for cornea grafts. For oncology, it develops and manufactures prognostic genomic tests for breast and prostate cancer. The group also markets a comprehensive portfolio of molecular tests for detecting infectious diseases, alongside solutions for immunology, fertility, and dermatological conditions.

Recent filings

Filing Released Lang Actions
EUROBIO SCIENTIFIC : CALENDRIER DES PUBLICATIONS FINANCIÈRES DU 2EME SEMESTRE
Report Publication Announcement Classification · 98% confidence The document is titled "CALENDRIER DES PUBLICATIONS FINANCIÈRES DU 2EME SEMESTRE 2024" (Financial Publication Calendar for the Second Half of 2024). It explicitly lists future dates for key announcements, such as 'Chiffre d'affaires du 1er semestre 2024' (H1 2024 Revenue) and 'Résultats du 1er semestre 2024' (H1 2024 Results). This document is an announcement about the schedule of future financial reports, not the reports themselves. Since it is an announcement regarding the publication timing of reports, the most appropriate classification is Report Publication Announcement (RPA). The document length is short (2445 chars), supporting the idea that it is an announcement rather than a full report.
2024-07-23 French
Eurobio Scientific : bilan semestriel du contrat de liquidité
Transaction in Own Shares Classification · 95% confidence The document is titled "BILAN SEMESTRIEL DU CONTRAT DE LIQUIDITE" (Half-Yearly Balance Sheet of the Liquidity Contract) dated July 3, 2024, reporting data up to June 30, 2024. It details the activity (purchases and sales of shares) under a liquidity contract over the first semester (1er semestre) of 2024. This is a periodic report detailing the status of a specific financial arrangement (liquidity contract/market making) over a six-month period. This fits the description of a comprehensive financial report for a period shorter than a year, which corresponds to an Interim / Quarterly Report (IR). Although it is not a full statutory financial report, it is a mandatory periodic disclosure related to market stability and share trading, making IR the most appropriate category among the choices, as it covers a defined interim period (six months). It is not an Earnings Release (ER) as it focuses on liquidity management, not core operational results.
2024-07-03 French
EUROBIO SCIENTIFIC SIGNE UN ACCORD POUR L'ACQUISITION DU TEST D'EXPRESSION GÉNIQUE POUR LE CANCER DU SEIN ENDOPREDICT®
M&A Activity Classification · 98% confidence The document is a press release dated May 7, 2024, announcing that Eurobio Scientific has signed an agreement to acquire the intellectual property rights for the EndoPredict® breast cancer gene expression test from Myriad Genetics. This announcement details a significant corporate transaction (M&A activity) involving the acquisition of assets and subsequent licensing agreements. This fits the definition of M&A Activity (TAR). It is not a full annual report (10-K), an earnings release (ER), or a general regulatory filing (RNS), as it describes a specific strategic transaction.
2024-05-07 French
EUROBIO SCIENTIFIC SIGNS AN AGREEMENT TO ACQUIRE GENE EXPRESSION TEST FOR BREAST CANCER ENDOPREDICT®
M&A Activity Classification · 98% confidence The document is a press release dated May 7, 2024, announcing that Eurobio Scientific has signed an agreement to acquire the rights to the EndoPredict® gene expression test from Myriad Genetics. This announcement details a significant corporate transaction (acquisition) and its strategic implications (expansion in oncology, portfolio strengthening). This type of announcement, detailing a merger or acquisition proposal, directly corresponds to the M&A Activity category. It is not a formal regulatory filing like a 10-K or IR, nor is it a short announcement about publishing another report (RPA/RNS). It is the primary announcement of the transaction itself. Therefore, the appropriate code is TAR (M&A Activity).
2024-05-07 English
Eurobio Scientific : mise à disposition du rapport financier annuel 2023
Audit Report / Information Classification · 98% confidence The document is titled "MISE À DISPOSITION DU RAPPORT FINANCIER ANNUEL 2023" (Making available of the 2023 Annual Financial Report). It explicitly states that Eurobio Scientific has made available and filed its annual financial report for the year ended December 31, 2023, with the AMF (Autorité des Marchés Financiers). However, the document itself is very short (2664 characters) and its primary function is to announce that the report is available on the company website and has been filed. According to Rule #2 (The "MENU VS MEAL" Rule), a short announcement stating that a report has been published or made available should be classified as a Report Publication Announcement (RPA), rather than the full report itself (which would typically be a 10-K or IR, but this is a French filing context, and the document is clearly an announcement). Therefore, RPA is the most appropriate classification. FY 2023
2024-04-26 French
EUROBIO SCIENTIFIC: RESULTAT ANNUEL 2023
Earnings Release Classification · 100% confidence The document is titled "RESULTAT ANNUEL 2023" (Annual Results 2023) and presents detailed consolidated financial tables for the year 2023 compared to 2022, including revenue, gross margin, EBITDA, net result, and cash flow analysis. The text explicitly states that Eurobio Scientific "présente aujourd'hui ses résultats annuels consolidés 2023". Although it is a press release format, the content is the comprehensive annual financial performance summary, which aligns best with the Annual Report (10-K) category, as it covers the full fiscal year performance. However, since this is a press release announcing the results, it could also be classified as an Earnings Release (ER) or Management Report (MDA). Given the depth of the financial tables and the explicit mention of 'résultats annuels consolidés 2023', it is a primary financial disclosure. In the context of European filings where a formal 10-K equivalent might not be the primary document, this comprehensive annual results announcement is closest to the spirit of the Annual Report (10-K) or a detailed Interim/Quarterly Report (IR) if it were for a shorter period. Since it is explicitly 'ANNUEL', and it contains the full financial breakdown, it is a strong candidate for 10-K, but often these detailed press releases are classified as Earnings Release (ER) or Management Reports (MDA) if the actual statutory 10-K filing is separate. Since it contains the full financial statements and analysis, it is more than just an 'ER' (key highlights only). It is a detailed report. Given the options, and the comprehensive nature covering the entire year, I will lean towards the most comprehensive financial report type available, which is 10-K, or MDA if it's primarily management commentary on the results. The structure strongly suggests a detailed financial report release. Since it is a full-year report, and the content is extensive financial data, it is classified as a comprehensive annual financial disclosure. If a formal 10-K is not filed, this serves that purpose. I will select ER as the most common classification for detailed press releases announcing annual results, but MDA is also plausible. Re-evaluating: The document contains detailed tables and analysis covering the entire year, which is characteristic of a full annual report disclosure, even if presented as a press release. However, the presence of the note that audit procedures are still ongoing ('Les procédures d'audit des comptes par les commissaires aux comptes sont encore en cours') suggests this is the preliminary/unaudited annual results announcement, making it a strong candidate for an Earnings Release (ER) or Management Discussion & Analysis (MDA). Given the depth, MDA (Management's detailed explanation of financial results) is a very strong fit, as it explains the results in detail following the figures. I will choose MDA over ER because it goes beyond 'key highlights' and provides extensive narrative analysis of the figures, strategy, and outlook. FY 2023
2024-04-10 French

Browse filings by year

10 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.